The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-β-hydroxylase

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 15, 2010, Pages 4324-4327

  Adams, Christopher M ^a   Hu, Chii Whei ^a   Jeng, Arco Y ^a   Karki, Rajeshri ^a   Ksander, Gary ^a   Lasala, Dan ^a   Leung Chu, Jennifer ^a   Liang, Guiqing ^a   Liu, Qian ^a   Meredith, Erik ^a   Rao, Chang ^a   Rigel, Dean F ^a   Shi, Jie ^a   Smith, Sherri ^a   Springer, Clayton ^a   Zhang, Chun ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Aldosterone; Aldosterone synthase inhibitor; CYP11B1; CYP11B2; Hypertension

Indexed keywords

ALDOSTERONE SYNTHASE; BENZENESULFONAMIDE DERIVATIVE; ENZYME INHIBITOR; FAD 286; FADROZOLE; IMIDAZOLE DERIVATIVE; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; ENANTIOMER; IC 50;

ALDOSTERONE SYNTHASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; IMIDAZOLES; STEROID 11-BETA-HYDROXYLASE; SULFONAMIDES;

EID: 77955426300     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.086     Document Type: Article

References (31)

1. J.S. Williams, and G.H.J. Williams Clin. Endocrinol. Metab. 88 2003 2364
2. X. Hu, and C.W. Bolton Drug Dev. Res. 67 2006 871
3. M.N. Pratt-Ubunama, M.K. Nishizaka, and D.A. Calhoun Curr. Hypertens. Rep. 7 2005 186
4. Two clinical trials, RALES and EPHESUS have shown these agents to be beneficial for the treatment of heart failure; see: B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes N. Engl. J. Med. 341 1999 709
5. B. Pitt, W.J. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin N. Engl. J. Med. 348 2003 1309
6. M. Wehling J. Mol. Med. 73 1995 439
7. M. Kushibiki, M. Yamada, K. Oikawa, H. Tomita, T. Osanai, and K. Okumura Eur. J. Pharmacol. 572 2007 182
8. This approach has also been pursued by Hartmann and co-workers; see: R.W. Hartmann, U. Muller, and P.B. Ehmer Eur. J. Med. Chem. 38 2003 363
9. S. Ulmschneider, M. Negri, M. Voets, and R.W. Hartmann Bioorg. Med. Chem. Lett. 16 2006 2
10. M. Voets, I. Antes, C. Scherer, U. Müller-Viera, K. Biemel, S. Marchais-Oberwinkler, and R.W. Hartmann J. Med. Chem. 49 2006 2222
11. S. Lucas, R. Heim, C. Ries, K.E. Schewe, B. Birk, and R.W. Hartmann J. Med. Chem. 51 2008 8077
12. C. Ries, S. Lucas, R. Heim, B. Birk, and R.W. Hartmann J. Steroid Biochem. Mol. Biol. 116 2009 121 and references therein
13. W.E. Rainey Mol. Cell Endrocrinol. 151 1999 151 and references therein
14. M. Bureik, M. Lisurek, and R. Bernhardt Biol. Chem. 383 2002 1537
15. P.F. Trunet, P. Mueller, F. Girard, B. Aupetit, A.S. Bhatnagar, F. Zognbi, F. Ezzet, and J. Menard J. Clin. Endocrinol. Metab. 74 1992 571
16. J. Ménard, and L. Pascoe J. Hypertens. 24 2006 993
17. D. LaSala, A. Jeng, and Y. Shibanaka Anal. Biochem. 394 2009 56
18. E. Mornet, J. Dupont, A. Vitek, and P.C. White J. Biol. Chem. 264 1989 20961
19. The human CYP11B1 and CYP11B2 homology models were constructed using crystal structure of CYP3A4 (PDB code 1TQN ) as a template. Model construction was done using Prime version 1.5, Schrödinger, LLC, New York, NY. In the generated models, the loops were first refined using the PRIME structure refinement tool followed by stepwise minimization using the OPLS forcefield. The parameters for heme were generated using the hetgrpffgen utility available from Schrödinger.
20. All compounds depicted are single isomers (i.e., >98% de and/or >98% ee) unless otherwise noted. The separation of stereoisomers was accomplished via HPLC, employing columns with chiral stationary phases.
21. Typically, the enantiomeric configuration was not determined. The data reported in this manuscript relates to the enantiomer with the preferred in vitro profile.
22. McKenna, J. Preparation of imidazopyrazines and imidazodiazepines as agents for the treatment of aldosterone mediated conditions. WO 2004014914A1.
23. A more detailed discussion of the development of this series will be reported in due course.
24. 1/2) was derived by monitoring the disappearance of test compound over a short period of time (e.g., 30 min). See: R.S. Obach Drug Metab. Dispos. 27 1999 1350
25. J.C. Kalvass, D.A. Tess, C. Giragossian, M.C. Linhares, and T.S. Maurer Drug Metab. Dispos. 29 2001 1332
26. N. Chauret, A. Gauthier, and D.A. Nicoll-Griffith Drug Metab. Dispos. 26 1997 1
27. M.B. Fisher, K. Campanale, B.L. Ackermann, M. VandenBranden, and S.A. Wrighton Drug Metab. Dispos. 28 2000 560
28. The human CYP19 assay was performed according to the method of: D.M. Stresser, S.D. Turner, J. McNamara, P. Stocker, V.P. Miller, C.L. Crespi, and C.J. Patten Anal. Biochem. 284 2000 427
29. Metabolite identification: Test articles were incubated in pooled human liver microsomes (BD Gentest, Woburn, MA) in the presence of cofactors, such as NADPH (oxidative metabolism) and UDPGA (conjugated metabolism). Following in vitro incubation and protein precipitation, samples were analyzed by LC/MS/MS for detection and characterization of the metabolites formed.
30. This compound was profiled as the racemate.
31. L. Bell, S. Bickford, P.H. Nguyen, J. Wang, T. He, B. Zhang, Y. Friche, A. Zimmerlin, L. Urban, and D. Bojanic J. Biomol. Screen. 13 2008 343